|Bid||5.15 x 100|
|Ask||9.77 x 3000|
|Day's Range||7.50 - 8.10|
|52 Week Range||7.20 - 21.59|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.83|
LIVONIA, Mich., Nov. 22, 2017-- Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia ...
Gemcabene reduced LDL-C by 20% and hsCRP by 53% when added to moderate intensity statin therapy. In cardiometabolic patients gemcabene improves atherogenic burden and reduces inflammation. LIVONIA, Mich., ...
BioVie Inc. , a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, today welcomed Mina Sooch, a highly seasoned biopharma ...
Data Support Clinical Evaluation of Gemcabene as a Potential Treatment For NAFLD/NASH. Clinical Trial in NAFLD/NASH Planned to Begin 4 Q-2017. LIVONIA, Mich., Oct. 23, 2017-- Gemphire Therapeutics Inc., ...
COBALT-1 results show significant LDL-C lowering for FH patients, including a mean reduction in LDL-C of 39% in the HeFH population. Gemcabene demonstrates novel mechanism to significantly lower LDL-C ...
New analysis of data shows clinically meaningful reductions in LDL-C and hsCRP across multiple trials and confirms support to advance gemcabene into Phase 3. End of Phase 2 meetings planned for early 2018. ...
LIVONIA, Mich., Sept. 18, 2017-- Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia ...
Gemphire Therapeutics Inc (GEMP) has moved higher as of late, but there could definitely be trouble on the horizon for this company.